Logo

ATAI

Atai Beckley N.V

ATAI

Atai Beckley N.V • NASDAQ
$3.89 ▲ 3.73% (+0.14)
Market Cap $845.95 M
52w High $6.75
52w Low $1.15
Dividend Yield 0%
P/E -4.69
Volume 2.28M
Outstanding Shares 217.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $749K ▲ $29.185M ▲ $-61.074M ▼ -8.154K% ▼ $-0.28 ▼ $-60.734M ▼
Q2-2025 $719K ▼ $25.992M ▲ $-27.729M ▼ -3.857K% ▼ $-0.14 ▲ $-27.162M ▼
Q1-2025 $1.555M ▲ $11.087M ▼ $-26.431M ▲ -1.7K% ▼ $-0.15 ▲ $-19.054M ▲
Q4-2024 $-5K ▼ $30.26M ▲ $-38.958M ▼ 779.16K% ▲ $-0.24 ▼ $-38.007M ▼
Q3-2024 $40K $22.642M $-26.286M -65.715K% $-0.16 $-25.597M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $114.606M ▲ $239.82M ▲ $79.912M ▲ $159.751M ▲
Q2-2025 $95.943M ▼ $189.204M ▼ $45.279M ▲ $143.738M ▼
Q1-2025 $98.204M ▲ $195.783M ▲ $43.509M ▲ $152.053M ▲
Q4-2024 $62.33M ▼ $159.387M ▼ $42.833M ▼ $116.297M ▼
Q3-2024 $85.92M $197.519M $51.203M $145.72M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-61.098M ▼ $-23.261M ▼ $-67.553M ▼ $59.744M ▲ $-31.538M ▼ $-28.624M ▼
Q2-2025 $-27.746M ▼ $-14.094M ▲ $9.784M ▲ $7.757M ▼ $3.653M ▼ $-19.221M ▼
Q1-2025 $-26.465M ▲ $-17.841M ▲ $-11.014M ▼ $59.605M ▲ $30.782M ▲ $-18.109M ▲
Q4-2024 $-38.991M ▼ $-24.295M ▼ $6.56M ▼ $154K ▼ $-17.458M ▼ $-24.384M ▼
Q3-2024 $-26.311M $-19.341M $24.84M $4.894M $10.63M $-19.342M

Revenue by Products

Product Q4-2022Q1-2025Q2-2025Q3-2025
License
License
 $0 ▲$0 ▲$0 ▲$0 ▲
Research And Development Services
Research And Development Services
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Atai is still very much a development-stage company. It has essentially no product revenue yet, so the income statement is driven almost entirely by research and operating expenses. Losses have been consistent year after year, with only modest variation, reflecting a steady investment in clinical programs rather than any mature commercial business. Per‑share losses remain meaningful, which is typical for an early-stage biotech that is funding a broad pipeline without offsetting sales.

Balance Sheet

Balance Sheet The balance sheet shows a company that once held a strong cash position after going public but has been drawing that down over time. Total assets and cash have both stepped down from earlier highs, while shareholder equity has shrunk as cumulative losses have built up. Debt remains small, which limits financial strain from interest, but the overall financial cushion is now much thinner than a few years ago, increasing the importance of future financing or partnership support.

Cash Flow

Cash Flow Cash flow is characterized by a steady cash burn from operations tied to R&D and overhead, with no meaningful inflows from products and virtually no spending on physical assets or equipment. Free cash flow is negative but relatively stable, signaling disciplined but ongoing cash usage rather than uncontrolled spending. The pattern is typical of a biotech funding clinical trials, but it also means the company’s future progress depends heavily on access to new capital as existing cash is consumed.

Competitive Edge

Competitive Edge Atai operates in a highly specialized area of mental health, focusing on psychedelic and next‑generation neuropsychiatric treatments. Its edge comes from a diversified pipeline, short‑duration psychedelic formulations, and the use of AI‑assisted drug discovery. The combination with Beckley Psytech and FDA Breakthrough Therapy designation for a key depression candidate strengthen its profile versus peers. That said, the space is crowded, regulatory hurdles are high, and commercial models for psychedelic care are still evolving, so its competitive position remains promising but unproven.

Innovation and R&D

Innovation and R&D Innovation is the clear center of gravity for Atai. The company is advancing multiple differentiated programs, including fast‑acting intranasal psychedelics for depression, a cognitive enhancer for schizophrenia‑related impairment, novel treatments for social anxiety, and non‑hallucinogenic compounds for opioid use disorder. Its use of AI to design safer, more targeted molecules and its focus on shorter, more scalable treatment sessions are notable strategic choices. However, most programs are still in mid‑stage clinical development, so scientific and regulatory outcomes over the next few years will be critical in validating this R&D strategy.

Summary

Atai is a classic high‑risk, high‑uncertainty biotech story: no established revenues, ongoing operating losses, and a shrinking but still positive capital base, all supporting an ambitious mental‑health pipeline. Financially, the company appears lean, dependent on external funding over time, and fully oriented toward R&D rather than near‑term profitability. Strategically, it is positioned at the forefront of psychedelic and novel neuropsychiatric therapies, with multiple potential shots on goal and visible clinical milestones ahead. The overall picture is a company with meaningful scientific and strategic upside potential, balanced by significant funding needs and the usual binary risks of clinical and regulatory outcomes.

NEWS

November 19, 2025 · 7:32 PM UTC

Enhanced Fortifies Executive Leadership Team & Board of Directors

Read more

October 20, 2025 · 5:29 PM UTC

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Read more

October 16, 2025 · 10:31 PM UTC

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Read more

October 16, 2025 · 4:12 PM UTC

atai Life Sciences Announces Proposed Public Offering of Common Shares

Read more

October 16, 2025 · 4:10 PM UTC

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Read more